The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan
Status: | Recruiting |
---|---|
Conditions: | Peripheral Vascular Disease, Renal Impairment / Chronic Kidney Disease, Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases, Nephrology / Urology |
Healthy: | No |
Age Range: | 50 - Any |
Updated: | 4/21/2016 |
Start Date: | November 2010 |
End Date: | December 2016 |
Contact: | Kambiz Zandi- Nejad, MD |
Email: | kzandinejad@partners.org |
Phone: | 617-732-5700 |
The hypothesis is that switching calcium based phosphate binders to sevelamer carbonate will
be associated with less inflammation including less atherosclerotic plaque inflammation
(inflammation of the vessel walls).
be associated with less inflammation including less atherosclerotic plaque inflammation
(inflammation of the vessel walls).
Inclusion Criteria:
- A signed consent form;
- Male or Female, 50 years or older;
- Diagnosed with end stage renal disease (ESRD), on maintenance hemodialysis for at
least three (3) months;
- On calcium-based phosphate binders;
- Subject must be able to understand and provide informed consent;
- No known contraindications to therapy with sevelamer carbonate.
Exclusion Criteria:
- Any patient with a medical condition or taking any medications that would be
contraindicated with the use of sevelamer carbonate, such as history of bowel
obstruction;
- History of severe allergic reactions to the study medication;
- History of active infection (other than a simple respiratory tract infection) or
acute gouty attack within 2 weeks prior to enrollment;
- Known serological positivity for Human Immunodeficiency Virus (HIV), Hepatitis B
surface Antigen (HBsAg), or Hepatitis C Virus Antibody (HCV Ab) except dose with
normal liver function tests (AST, ALT, Bilirubin, and Alkaline Phophatase) and no
history of cirrhosis;
- Elevation of liver function tests at time of entry (Aspartate Aminotransferase (AST)
and/or Alanine Aminotransferase (ALT) > 2 times the upper limit of normal);
- History of drug, alcohol, or chemical abuse within 6 months prior to enrollment;
- History of malignancy except those adequately treated, has completed treatment and
clinically in remission for more than 6 month; adequately treated in-situ cervical
carcinoma, or adequately treated basal or squamous cell carcinoma of the skin;
- History of an inflammatory disease such as systemic lupus erythematosus (SLE),
rheumatoid arthritis or ulcerative colitis except those in remission for more than 6
months;
- Patients currently on sevelamer carbonate or sevelamer chloride or history of taking
them for more than a week in the past three months;
- Patients receiving chronic anti-inflammatory therapy;
- Patients in whom FDG-PET/CT dual scans are contraindicated.
We found this trial at
10
sites
Boston, Massachusetts 02130
Principal Investigator: Kambiz ZANDI-NEJAD, MD
Phone: 617-732-5700
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Kambiz ZANDI-NEJAD, MD
Phone: 617-732-5700
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials